Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
Monte Rosa Therapeutics reported a net loss of $44.5 million for the three months ended March 31, 2026, compared with net income of $46.9 million a year earlier. Collaboration revenue fell to $4.2 million from $84.9 million as prior-period payments were not repeated.
Research and development expense rose to $44.1 million, reflecting broader pipeline activity, while general and administrative costs increased modestly to $10.2 million. The company ended the quarter with $666.2 million in cash, cash equivalents and marketable securities and $671.2 million including restricted cash, and expects this to fund operations into 2029.
Monte Rosa Therapeutics reported a first quarter 2026 net loss of $44.5 million, compared with net income of $46.9 million a year earlier, as collaboration revenue normalized after large 2025 milestone payments. Q1 2026 collaboration revenue fell to $4.2 million from $84.9 million.
Research and development expenses rose to $44.1 million and general and administrative costs to $10.2 million, reflecting expansion of clinical and discovery programs. Cash, cash equivalents, restricted cash, and marketable securities reached $671.2 million, and the company expects this balance to fund operations into 2029 while it advances multiple Phase 2 studies and new IND filings.
Monte Rosa Therapeutics President & CEO Markus Warmuth reported an open-market sale of 5,467 shares of common stock. The shares were sold at a weighted average price of $18.922 per share, in multiple trades between $18.67 and $19.38.
After the transaction, Warmuth directly holds 600,004 shares of Monte Rosa Therapeutics. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025, indicating the transaction timing was set in advance rather than being purely discretionary.
Monte Rosa Therapeutics Inc. notice of a proposed sale of Common shares under a Form 144, listing Rockefeller Capital Management as the broker and NASDAQ as the market.
The excerpt shows a RSU stock award of 21,865 shares dated 01/02/2025 with a related date 01/02/2026. It also records recent dispositions by Markus Warmuth: an entry dated 03/02/2026 with $97,974.22 and a sale on 04/14/2026 of 8,000 shares for $141,124.80.
Monte Rosa Therapeutics has called a fully virtual 2026 annual stockholder meeting for June 11, 2026 at 8:30 a.m. Eastern Time, with access via pre‑registration at www.proxydocs.com/GLUE. Stockholders of record as of April 16, 2026, when 84,382,573 common shares were outstanding, may vote.
Investors will elect three Class II directors—Andrew Schiff, Chandra Leo and Anthony Manning—for terms running to the 2029 meeting, using a plurality standard, and vote on ratifying Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026. The board recommends voting “FOR” both proposals.
The filing outlines Nasdaq independence determinations, committee structures and director retainers, and details 2025 executive pay. In 2025, CEO Markus Warmuth received a $650,000 salary, $429,000 cash incentive and equity awards that brought total reported compensation to $5,032,728, while Monte Rosa continued to use “emerging growth company” scaled disclosures.
Monte Rosa Therapeutics (common stock) filing a Schedule 13G/A (Amendment No. 2) reports beneficial ownership by Dimension-related entities and affiliated individuals. The cover pages show shared voting and dispositive power over 6,513,765 shares for several reporting persons and 5,663,265 and 850,500 shares held directly by Dimension Capital I and Dimension Capital II, respectively. The percentages use a baseline of 80,015,667 shares outstanding as of March 2, 2026.
GLUE filed a Form 144 notice reporting an intended sale of 18,683 shares of Common Stock via a stock option exercise, dated 04/16/2026.
The filing lists prior sales by the same holder during the past three months including 25,164 shares on 02/27/2026 and 26,117 shares on 04/08/2026.
Monte Rosa Therapeutics President & CEO Markus Warmuth reported an open-market sale of 8,000 shares of Common Stock. The sale occurred on April 14, 2026 at a weighted average price of $17.6406 per share, with individual trade prices ranging from $17.64 to $17.65. After this transaction, he directly holds 605,471 shares of Monte Rosa Therapeutics common stock, indicating he retains a substantial equity position in the company.
Markus Warmuth reported the sale of 5,466 shares of Common Stock under Rule 144. The sale is shown with a proceeds figure of $97,974.22 and relates to restricted shares originally dated 09/01/2020. The Form 144 lists 8,000 restricted shares associated with the issuer record.